乌帕替尼治疗对生物制剂改善病情抗风湿药无效的活动性类风湿关节炎患者的安全性和有效性(SELECT-BEYOND):一项双盲、随机对照3期试验
该双盲、随机对照3期试验在26个国家153个中心纳入499例对bDMARDs应答不佳或不耐受且正在使用csDMARDs的活动性类风湿关节炎患者,按2:2:1:1随机接受乌帕替尼15mg、30mg或安慰剂每日一次口服12周,之后均接受乌帕替尼治疗。第12周ACR20达标率:乌帕替尼15mg组65%、30mg组56%、安慰剂组28%(各剂量与安慰剂比较p<0.0001);DAS28(CRP)≤3.2达标率:15mg组43%、30mg组42%、安慰剂组14%(各剂量与安慰剂比较p<0.0001)。总体不良事件发生率安慰剂组56%、15mg组55%、30mg组67%;30mg组严重不良事件、严重感染、带状疱疹及导致停药的不良事件多于15mg组和安慰剂组。
要点
- 对bDMARDs应答不佳的活动性RA患者,乌帕替尼15mg每日一次口服12周ACR20达标率65%(95%CI 57-72),安慰剂组28%(22-35),p<0.0001。
- 乌帕替尼30mg组12周ACR20达标率56%(49-64),安慰剂组28%(22-35),p<0.0001。
- 乌帕替尼15mg组12周DAS28(CRP)≤3.2达标率43%(36-51),30mg组42%(35-50),安慰剂组14%(9-20),各剂量与安慰剂比较p<0.0001。
- 总体不良事件:安慰剂组56%、乌帕替尼15mg组55%、30mg组67%;30mg组严重不良事件7%,15mg组5%,安慰剂组无严重不良事件报告。
- 30mg组严重感染、带状疱疹及导致停药的不良事件多于15mg组和安慰剂组;安慰剂对照阶段乌帕替尼组报告1例肺栓塞、3例恶性肿瘤、1例主要不良心血管事件和1例死亡,安慰剂组无报告。
适用人群与场景
- 年龄18岁及以上、患有活动性类风湿关节炎、既往对bDMARDs应答不佳或不耐受、且正在接受背景csDMARDs治疗的患者。
- 研究纳入对bDMARDs应答不佳或不耐受的患者,未报告其他纳入或排除标准。
诊断标准与关键阈值
- 主要终点之一:第12周达到美国风湿病学会标准20%改善(ACR20)的患者比例。
- 主要终点之一:第12周28关节疾病活动度评分(基于C反应蛋白,DAS28[CRP])≤3.2的患者比例。
处置流程与药物剂量
- 患者按2:2:1:1随机分配至口服乌帕替尼缓释片15mg每日一次、30mg每日一次或安慰剂,治疗12周;第12周起乌帕替尼15mg或30mg组继续相应剂量,安慰剂组分别转为乌帕替尼15mg或30mg。
- 乌帕替尼为口服缓释制剂,每日一次给药;原文未报告其他合并用药调整方案。
红旗征与不能漏的情况
- 安慰剂对照阶段乌帕替尼组报告1例肺栓塞、3例恶性肿瘤、1例主要不良心血管事件和1例死亡,安慰剂组无报告。
- 乌帕替尼30mg组严重感染、带状疱疹及导致停药的不良事件多于15mg组和安慰剂组。
研究设计与关键结果
- 研究类型:双盲、随机对照3期试验,在26个国家153个中心进行,纳入499例对bDMARDs应答不佳或不耐受的活动性RA患者,随机分为乌帕替尼15mg组165例、30mg组165例、安慰剂后转15mg组85例、安慰剂后转30mg组84例;1例15mg组患者在治疗开始前退出。
- 患者平均病程13.2年(SD 9.5);235例(47%)既往使用过1种bDMARD,137例(28%)使用过2种,125例(25%)使用过至少3种;451例(91%)完成12周治疗,419例(84%)完成24周治疗。
- 第12周ACR20达标率:乌帕替尼15mg组106/164(65%,95%CI 57-72),30mg组93/165(56%,49-64),安慰剂组48/169(28%,22-35);各剂量与安慰剂比较p<0.0001。
- 第12周DAS28(CRP)≤3.2达标率:乌帕替尼15mg组71/164(43%,36-51),30mg组70/165(42%,35-50),安慰剂组24/169(14%,9-20);各剂量与安慰剂比较p<0.0001。
- 截至第12周总体不良事件:安慰剂组95/169(56%),乌帕替尼15mg组91/164(55%),30mg组111/165(67%)。
- 第12周任一组发生率≥5%的最常见不良事件:上呼吸道感染安慰剂组13/169(8%)、15mg组13/164(8%)、30mg组10/165(6%);鼻咽炎11/169(7%)、7/164(4%)、9/165(5%);尿路感染10/169(6%)、15/164(9%)、9/165(5%);类风湿关节炎加重10/169(6%)、4/164(2%)、6/165(4%)。
- 严重不良事件:乌帕替尼30mg组12/165(7%),15mg组8/164(5%),安慰剂组无报告。
证据类型、等级与局限
- 证据类型:双盲、随机对照3期试验;资助方为AbbVie Inc.。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于对bDMARDs应答不佳或不耐受且正在使用csDMARDs的活动性RA患者,乌帕替尼15mg或30mg每日一次口服12周可较安慰剂显著提高ACR20和DAS28(CRP)≤3.2达标率。
- 乌帕替尼30mg组总体不良事件、严重不良事件、严重感染、带状疱疹及导致停药的不良事件多于15mg组和安慰剂组。
- 原文未据此给出推荐。
指南或共识出处
- SELECT-BEYOND试验,ClinicalTrials.gov注册号NCT02706847,发表于Lancet。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate response to biologic disease-modifying anti-rheumatic drugs (bDMARDs).
METHODS: We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs). We randomly assigned patients (2:2:1:1) by interactive response technology to receive once-daily oral extended-release upadacitinib 15 mg or 30 mg or placebo for 12 weeks, followed by upadacitinib 15 mg or 30 mg from week 12 onwards. The two separate primary endpoints were the proportions of patients achieving a 20% improvement in American College of Rheumatology criteria (ACR20) at week 12 and the proportion of patients achieving a 28-joint disease activity score using C-reactive protein (DAS28[CRP]) of 3·2 or less at week 12. Efficacy and safety analyses were done in the modified intention-to-treat population of all patients who received at least one dose of study drug. Data are presented up to week 24 of this ongoing study. The trial is registered with ClinicalTrials.gov (NCT02706847).
FINDINGS: Between March 15, 2016, and Jan 10, 2017, 499 patients were randomly assigned (n=165 upadacitinib 15 mg; n=165 upadacitinib 30 mg; n=85 placebo then upadacitinib 15 mg; and n=84 placebo then upadacitinib 30 mg) and one patient was withdrawn from the 15 mg upadacitinib group before the start of study treatment. Mean disease duration was 13·2 years (SD 9·5); 235 (47%) of 498 patients had received one previous bDMARD, 137 (28%) had received two, and 125 (25%) had received at least three; 451 (91%) patients completed treatment up to week 12 and 419 (84%) patients completed treatment up to week 24. At week 12, ACR20 was achieved by 106 (65%; 95% CI 57-72) of 164 patients receiving upadacitinib 15 mg and 93 (56%; 49-64) of 165 patients receiving upadacitinib 30 mg compared with 48 (28%; 22-35) of 169 patients receiving placebo (p<0·0001 for each dose vs placebo). DAS28(CRP) of 3·2 or less was achieved by 71 (43%; 95% CI 36-51) of 164 patients receiving upadacitinib 15 mg and 70 (42%; 35-50) of 165 patients receiving upadacitinib 30 mg versus 24 (14%; 9-20) of 169 patients receiving placebo (p<0·0001 for each dose vs placebo). Up to week 12, overall numbers of patients with adverse events were similar for the placebo group (95 [56%] of 169) and the upadacitinib 15 mg group (91 [55%] of 164), but higher in the upadacitinib 30 mg group (111 [67%] of 165). At week 12, the most common adverse events occurring in at least 5% of patients in any treatment group were upper respiratory tract infection (13 [8%] of 169 in the placebo group; 13 [8%] of 164 in the upadacitinib 15 mg group; ten [6%] of 165 in the upadacitinib 30 mg group), nasopharyngitis (11 [7%]; seven [4%]; nine [5%]), urinary tract infection (ten [6%]; 15 [9%]; nine [5%]), and worsening of rheumatoid arthritis (ten [6%]; four [2%]; six [4%]). The number of patients with serious adverse events was higher in the upadacitinib 30 mg group (12 [7%]) than in the upadacitinib 15 mg group (eight [5%]); no serious adverse events were reported in patients receiving placebo. More patients in the upadacitinib 30 mg group had serious infections, herpes zoster, and adverse events leading to discontinuation than in the upadacitinib 15 mg and placebo groups. During the placebo-controlled phase of the study, one case of pulmonary embolism, three malignancies, one major adverse cardiovascular event, and one death were reported in patients receiving upadacitinib; none were reported in patients receiving placebo.
INTERPRETATION: Both doses of upadacitinib led to rapid and significant improvements compared with placebo over 12 weeks in patients with refractory rheumatoid arthritis.
FUNDING: AbbVie Inc.
参考来源
- Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018. PMID: 29908670. doi:10.1016/S0140-6736(18)31116-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。